Last updated September 25, 2026 · Indication clarity
Mounjaro® vs Zepbound® dosing: same molecule, different US indications
Not affiliated with Eli Lilly. Mounjaro®, Zepbound®, and KwikPen® are trademarks of Eli Lilly and Company (or its affiliates). Educational only—not medical advice.
Both brands contain tirzepatide. They are separate FDA-approved Lilly products with different labeled uses. Do not switch brands or indications based on a website. Verify current indication language on FDA / DailyMed (checked as of September 25, 2026).
Indication snapshot (educational)
| Mounjaro® | Zepbound® | |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide |
| US brand role (high level) | Type 2 diabetes (see live label for full indication language, including any cardiovascular risk-reduction framing) | Chronic weight management and obstructive sleep apnea in indicated adult populations (see live label) |
| Dosing logistics | Weekly titration themes similar in class—follow the Mounjaro PI/IFU | Weekly titration themes—follow the Zepbound PI/IFU |
| DIY switch? | No. Clinician- and pharmacy-directed only. | |
We do not market Mounjaro as a weight-loss product. Weight-management labeling for tirzepatide in the US sits with Zepbound for appropriate patients. Any off-label use is a clinician decision—not web content.
Where to go deeper (sister site)
- SURMOUNT evidence — trial summaries (educational)
- Compounded vs Zepbound® — approval & quality framing
- Cost without insurance
- Side effects
- Mounjaro titration schedule (this site)
FAQ
Are the milligram strengths the same molecule?
Yes—both contain tirzepatide. Brands, labels, and presentations still differ. Follow the product prescribed.
Can I use Mounjaro for weight loss because a website said so?
No. Follow your clinician and the labeled product dispensed to you. US weight-management labeling for tirzepatide is under Zepbound for indicated populations.
Where do I read about SURMOUNT evidence?
On Tirzepatide Hub: surmount-evidence.